Copyright
©The Author(s) 2015.
World J Gastroenterol. Jan 14, 2015; 21(2): 408-422
Published online Jan 14, 2015. doi: 10.3748/wjg.v21.i2.408
Published online Jan 14, 2015. doi: 10.3748/wjg.v21.i2.408
Stage of CKD | Estimated GFR | Target dosage of ribavirin | Dosage of Interferon |
1 | ≥ 90 | 800 to 1200 mg qd1 | PEG-IFN α2a 180 μg qw or PEG-IFN α2b 1.5 μg/kg qw |
2 | 60 to 89 | 600 to 800 mg qd1 | |
3 | 30 to 59 | 400 to 600 mg qd1 | |
4 | 15 to 29 | 200 mg qd | PEG-IFN α2a 135 μg qwor PEG-IFN α2b 1.0 μg/kg qw |
5 | < 15 or HD | Titrated according to patient tolerability2 |
- Citation: Carvalho-Filho RJ, Feldner ACC, Silva AEB, Ferraz MLG. Management of hepatitis C in patients with chronic kidney disease. World J Gastroenterol 2015; 21(2): 408-422
- URL: https://www.wjgnet.com/1007-9327/full/v21/i2/408.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i2.408